Logiq Inc - LGIQ STOCK NEWS

Logiq, Inc. (OTC PINK:LGIQ) has announced a definitive agreement to acquire EVIMATE, a medical device innovation company, for $5 million. This acquisition marks Logiq's entry into the medical device sector. EVIMATE specializes in advanced vital sign monitoring products that utilize AI technology for comprehensive health metric tracking and predictive analytics.

EVIMATE's solution includes next-generation devices and a user-friendly app that continuously monitors key health indicators such as temperature, heart rate, ECG, blood pressure, oxygen levels, and glucose levels. The system is designed for Remote Patient Monitoring (RPM), providing real-time insights and alerts to healthcare providers, caregivers, and family members.

Additionally, EVIMATE has developed an automotive healthcare system for monitoring driver vitals, featuring sensors in the driver's seat and steering wheel to collect vital signs like heart functions, respiratory rate, stress level, and blood oxygen level. All devices mentioned will require FDA regulatory approvals and additional patent filings for IP protection.

Logiq, Inc. (OTC:LGIQ) has announced a definitive agreement to acquire MedLab Essentials, , a leader in cell and gene therapy innovation, in a deal valued at $100 million. The acquisition will be executed through a share exchange, with MedLab becoming a wholly owned subsidiary of Logiq. Key highlights include:

1. Logiq shareholders will retain 15% post-transaction
2. The combined entity aims to uplist to Nasdaq, CBOE, or NYSE
3. A substantial capital raise is planned by the end of 2024
4. This marks Logiq's first step in a series of biotech acquisitions targeting a cumulative value over $750 million

This strategic move signifies Logiq's diversification into the biotech sector, particularly focusing on cell and gene therapy assets.

Logiq has signed a binding letter of intent to acquire MedLab Essentials for $100 million in a share exchange deal. MedLab will become a wholly-owned subsidiary, with its executives joining Logiq's senior management.

This acquisition diversifies Logiq into the biotech sector and aims for a Nasdaq, CBOE, or NYSE uplisting by Q3 2024. Post-transaction, Logiq shareholders will retain 15% of the company. This is part of a broader strategy to expand into biotech and cell and gene therapy, targeting a cumulative value exceeding $750 million.

DLQ, Inc. provides an update on its pending merger with ABRI SPAC I, Inc. The registration statement for the merger has been declared effective by the SEC. Logiq has scheduled a special meeting of its stockholders on October 23, 2023, to seek approval for the merger. The combined company is expected to be renamed 'Collective Audience, Inc.' and listed on Nasdaq under the ticker symbols 'CAUD' and 'CAUDW'. The merger is expected to close in Q4 2023, subject to approvals.

Logiq reports Q2 2023 revenues of $4.86 million, increasing 37% sequentially and 47% YoY. Pending SPAC merger with ABRI SPAC I expected to provide a listing on a senior stock exchange. DataLogiq subsidiary SPAC merger in progress. Struggling IPO market increases value of public reporting companies like Logiq. Late-stage discussions with potential M&A targets. Park Place Payments business solid, growth dependent on funding. New product lines planned for launch. Acquisition targets expected to drive revenue growth.